杭州奥泰生物技术股份有限公司第三届监事会第十六次会议决议公告

Group 1 - The core point of the announcement is the approval of the 2025 interim profit distribution plan by the supervisory board, which is deemed beneficial for the company's sustainable development and aligns with legal regulations [3][12]. - The supervisory board meeting was held on September 18, 2025, with all three attending supervisors agreeing to waive the notice period requirements, confirming the legality and validity of the meeting [2][4]. - The profit distribution plan involves a cash dividend of 10 yuan (including tax) for every 10 shares, with no stock bonus or capital increase [7][10]. Group 2 - The total distributable profit available to the parent company as of June 30, 2025, is approximately 1.65 billion yuan, and the proposed cash dividend distribution totals approximately 78.31 million yuan, representing 59.32% of the net profit attributable to shareholders for the first half of 2025 [8][11]. - The distribution will be based on the total share capital after deducting shares held in the company's repurchase account, which amounts to 973,631 shares [8][9]. - The profit distribution plan does not require submission to the shareholders' meeting for approval, as it falls under the authority granted by the shareholders at the 2024 annual meeting [10][11].